Clinical Trials - ALMS

NCT IDTitleStatusPhasesStart DateCompletion DatePrimary Completion Date
NCT06962774An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal FunctionRECRUITINGPHASE12025-05-092025-122025-12
NCT06952634An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver DamageRECRUITINGPHASE12025-04-292025-122025-12
NCT06846541Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque PsoriasisRECRUITINGPHASE32025-01-082028-112028-11
NCT06588738A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001ACTIVE_NOT_RECRUITINGPHASE32024-08-202025-122025-09
NCT06586112A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque PsoriasisACTIVE_NOT_RECRUITINGPHASE32024-07-252025-122025-09
NCT05966480Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus ErythematosusACTIVE_NOT_RECRUITINGPHASE22023-06-262027-09-012026-07-01
NCT05953688POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIUTERMINATEDPHASE22023-06-142024-08-132024-08-13
NCT05739435Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque PsoriasisACTIVE_NOT_RECRUITINGPHASE22023-01-172026-12-302026-12-01
NCT05600036A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque PsoriasisCOMPLETEDPHASE22022-09-272023-07-252023-06-29
NCT05431634Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy ParticipantsCOMPLETEDPHASE12022-05-122022-12-312022-12-01
NCT05330858Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy ParticipantsCOMPLETEDPHASE12022-03-172022-09-202022-06-30